Is Amneal Pharmaceuticals, Inc. (AMRX) Halal?

NASDAQ Healthcare United States $3.8B
✗ NOT HALAL
Confidence: 90/100
Amneal Pharmaceuticals, Inc. (AMRX) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 64.6% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. Amneal Pharmaceuticals, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 64.6%
/ 30%
6.8%
/ 30%
22.6%
/ 30%
0.46%
/ 5%
✗ NOT HALAL
DJIM 64.6%
/ 33%
6.8%
/ 33%
22.6%
/ 33%
0.46%
/ 5%
✗ NOT HALAL
MSCI 73.1%
/ 33%
7.7%
/ 33%
25.6%
/ 33%
0.46%
/ 5%
✗ NOT HALAL
S&P 64.6%
/ 33%
6.8%
/ 33%
22.6%
/ 33%
0.46%
/ 5%
✗ NOT HALAL
FTSE 73.1%
/ 33%
7.7%
/ 33%
25.6%
/ 50%
0.46%
/ 5%
✗ NOT HALAL

Financial Highlights

P/E Ratio
53.9
Forward: 10.1
EPS
$0.22
P/B Ratio
-52.7
EV/EBITDA
9.6
EV: $6.2B
Revenue
$3.0B
Growth: 11.5%
Beta
1.3
High volatility
Current Ratio
2.2

Profitability

Gross Margin 37.4%
Operating Margin 14.1%
Net Margin 2.4%
Return on Assets (ROA) 7.3%

Cash Flow & Balance Sheet

Operating Cash Flow$340M
Free Cash Flow$226M
Total Debt$2.7B
Debt-to-Equity45095.5
Current Ratio2.2
Total Assets$3.7B

Price & Trading

Last Close$12.06
50-Day MA$13.55
200-Day MA$11.03
Avg Volume2.6M
Beta1.3
52-Week Range
$6.68
$15.42

About Amneal Pharmaceuticals, Inc. (AMRX)

CEO
Mr. Chirag K. Patel
Employees
8,700
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Exchange
NASDAQ
Market Cap
$3.8B
Currency
USD

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Amneal Pharmaceuticals, Inc. (AMRX) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Amneal Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Amneal Pharmaceuticals, Inc.'s debt ratio?

Amneal Pharmaceuticals, Inc.'s debt ratio is 64.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 73.1%.

What are Amneal Pharmaceuticals, Inc.'s key financial metrics?

Amneal Pharmaceuticals, Inc. has a market capitalization of $3.8B, trailing P/E ratio of 53.9, and revenue of $3.0B. The company maintains a gross margin of 37.4% and a net margin of 2.4%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.